Skip to content
lifestyle.utv.ie
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Nanobiotix S.A.
Nanobiotix Announces Launch of Global Follow-On Offering
May 20, 2026
Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer
May 17, 2026
Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer Study
May 5, 2026
Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technology
May 3, 2026
Voting Rights and Shares Capital of the Company
May 2, 2026
NANOBIOTIX Announces Presentation of First Data from a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer
April 30, 2026
NANOBIOTIX Statement Regarding Recent Media Speculation
April 30, 2026
Voting Rights and Shares Capital of the Company
April 28, 2026
NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial Results
April 1, 2026
NANOBIOTIX to Participate in Investor Conferences in March
February 25, 2026
1
2
Next Page
→